Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1224 (LINC01224)
- Target
- LINC01224
- Molecular classification
- Long non-coding RNA (lncRNA), Non-protein coding RNA, Competing endogenous RNA (ceRNA)
01
Overview
Long intergenic non-protein coding RNA 1224 (LINC01224) is an oncogenic long non-coding RNA broadly overexpressed in several human cancers. It functions mainly by acting as a competing endogenous RNA, sponging tumor suppressor microRNAs (notably miR-485-5p and miR-193a-5p), which leads to increased expression of pro-tumor proteins such as IGF2BP3, PAK4, AKT3, and CDK8. LINC01224 has been validated as promoting cell proliferation, migration, invasion, and inhibiting apoptosis in vitro and in vivo models of hypopharyngeal squamous cell carcinoma, epithelial ovarian cancer, endometrial carcinoma, and gastric cancer. Its expression correlates with poor prognosis, and knockdown reduces tumor growth, positioning it as a potential therapeutic target and prognostic biomarker in oncology
- Other names
- LINC01224CTB-175P5.4
02
Mechanism of action
Most mechanisms center on RNA inhibition, such as siRNA/shRNA-mediated knockdown of LINC01224, which disrupts its function as a microRNA sponge and restores tumor-suppressive microRNA activity (e.g., miR-485-5p)
03
Biological functions
Regulation of gene expression via sponging microRNAs (e.g., miR-485-5p and miR-193a-5p), thus modulating downstream mRNA targetsCell cycle regulation and cell proliferation (promotes proliferation in cancer cells)Inhibition of apoptosis (reduces programmed cell death in cancer cells)Promotion of cell migration and invasion (facilitates metastatic behaviors)
04
Disease associations
Cancer (including hypopharyngeal squamous cell carcinoma, epithelial ovarian cancer, endometrial carcinoma, and gastric cancer)Possible role as oncogene in other cancers
05
Safety considerations
lncRNA targeting is largely in experimental/preclinical stages, with general safety challenges including off-target effects, delivery efficiency, and unintended effects on global transcriptome regulationSpecific safety concerns for LINC01224-directed therapy have not yet been described in literature, since clinical application is pending
06
Interacting drugs
RNA interference (siRNA/shRNA)
1 more in the full profile.
07
Biomarkers
LINC01224 expression levels in tumor tissues may serve as prognostic biomarkers for disease progression and poor survival in hypopharyngeal squamous cell carcinoma, epithelial ovarian cancer, and endometrial carcinomamiR-485-5p levels may also be relevant, as they interact mechanistically with LINC01224
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 1224 (LINC01224).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1224 (LINC01224).